Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus XYZAL.
PHENERGAN VC vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
5 mg orally once daily in the evening.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine